Sign In
Buy DHR
$178.08
+1.97 (+1.12%)
At Close: Jun 03, 2026
Danaher (DHR) Surpasses Market Returns: Some Facts Worth Knowing
07:32pm, Monday, 11'th Dec 2023
Danaher (DHR) concluded the recent trading session at $221.35, signifying a +1.77% move from its prior day's close.
Danaher (DHR) Acquires Abcam to Boost Life Sciences Segment
10:32am, Thursday, 07'th Dec 2023
Danaher (DHR) acquires Abcam for $5.7 billion, thus adding to its Life Sciences portfolio. This move will facilitate the mapping of complex diseases and expedite the drug discovery process.
Danaher completes $5.7 billion acquisition of Abcam
08:14am, Wednesday, 06'th Dec 2023
Medical tools supplier Danaher said on Wednesday it has completed the $5.7 billion acquisition of Abcam , overcoming the initial opposition from the founder of the protein consumables maker.
Danaher (DHR) Declines More Than Market: Some Information for Investors
07:32pm, Tuesday, 05'th Dec 2023
The latest trading day saw Danaher (DHR) settling at $219.44, representing a -1.21% change from its previous close.
Danaher (DHR) Ascends While Market Falls: Some Facts to Note
07:33pm, Wednesday, 29'th Nov 2023
Danaher (DHR) concluded the recent trading session at $222.52, signifying a +1.72% move from its prior day's close.
Danaher Corporation (DHR) Presents at 6th Annual Evercore ISI HealthCONx Conference (Transcript)
06:04pm, Wednesday, 29'th Nov 2023
Danaher Corporation (NYSE:DHR ) 6th Annual Evercore ISI HealthCONx Conference November 29, 2023 3:00 PM ET Company Participants Rainer Blair - CEO Conference Call Participants Vijay Kumar - Evercore I
Danaher Corporation: A Good Contrarian Bet
05:26pm, Monday, 27'th Nov 2023
Danaher Corporation is facing near-term headwinds due to COVID-19-related demand normalization and customer inventory destocking in its Biotechnology segment. However, these headwinds are temporary, a
Danaher: Poised For Long-Term Growth Despite Near-Term Hurdles
02:36am, Sunday, 26'th Nov 2023
Danaher focuses on innovation for steady, high-value recurring revenue, driving financial stability. Aging population, longer lifespans, and tech advances drive Danaher's sector toward significant gro
3 Healthcare Stocks to Scoop Up as They Change the Medical Landscape
01:13pm, Wednesday, 22'nd Nov 2023
The U.S. continues to spend more money on healthcare than any other country. Healthcare spending totaled $4.3 trillion, according to the American Medical Association.
Danaher to Present at Evercore ISI HealthCONx Conference
04:15pm, Tuesday, 21'st Nov 2023
WASHINGTON , Nov. 21, 2023 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the Evercore ISI HealthCONx Conf
Last Call: 3 Growth Stocks to Buy Before New Year's Eve
07:16pm, Sunday, 19'th Nov 2023
In the shifting sands of the current stock market, discerning investors continue to navigate a labyrinth of uncertainties. Yet, the allure of long-term growth stocks remains undiminished.
Three value stock picks from a veteran manager with a good performance record
11:03am, Wednesday, 08'th Nov 2023
For many years through 2022, it was becoming more difficult for active fund managers to make the case for their services, when broad index funds, with lower fees, were performing so well. But the tech
A New Bull Market Is Coming! 3 Stocks Set to Soar 65% to 132% Higher
05:30pm, Wednesday, 01'st Nov 2023
Regardless of whether you're a Wall Street veteran or new to investing, the past four years have been a roller coaster ride. A global pandemic brought a 14-year-long bull market to a screeching halt.
Make Me a Millionaire: 3 Top Growth Stocks to Buy Now
02:21pm, Wednesday, 01'st Nov 2023
The stock market is on the downswing. Many traders are dumping their holdings as inflation, interest rates, and geopolitical crises weigh heavily on sentiment.
Danaher's (DHR) Q3 Earnings & Revenues Beat, Decline Y/Y
01:32pm, Tuesday, 24'th Oct 2023
While Danaher (DHR) surpasses Q3 earnings and revenue estimates, the company's performance is hurt by a decrease in the sale of COVID-related products and weak demand in the Life Sciences segment.
